Olaparib, a PARP inhibitor, has been applied to treatment of metastatic PCa with DNA repair defects, and it has been confirmed that such patients can derive a survival benefit (Mateo et al., 2015). This evidence concerns the gene PARP1 and posterior cortical atrophy.